14513-15-6
14513-15-6 結(jié)構(gòu)式
基本信息
SIRT1和SIRT1抑制劑(CAMBINOL)
5-[(2-羥基萘-1-基)甲基]-6-苯基-2-硫代-2,3-二氫嘧啶-4(1H)-酮
NSC 112546
NSC-1125476
CAMBINOL
NSC-1125476
SIRT1/2 Inhibitor IV
Cambinol - NSC 112546
SIRT1/2 Inhibitor IV, Cambinol
5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone
5-[(2-Hydroxy-1-naphthyl)methyl]-6-phenyl-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone
5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one
物理化學性質(zhì)
安全數(shù)據(jù)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/06 | C3535 | Cambinol Cambinol | 14513-15-6 | 5mg | 130元 |
| 2026/06/06 | C3535 | Cambinol Cambinol | 14513-15-6 | 25mg | 590元 |
| 2026/06/05 | HY-100732R | SIRT1/2 INHIBITOR IV Cambinol (Standard) | 14513-15-6 | 5 mg | 2258元 |
常見問題列表
| Target | Value |
|
nSMase2
(Cell-free assay) | 7 μM(Ki) |
Cambinol inhibits NAD-dependent deacetylase activity of human SIRT1 and SIRT2. Inhibition of SIRT1 activity with cambinol during genotoxic stress leads to hyperacetylation of key stress response proteins and promotes cell cycle arrest. Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induces apoptosis, which is accompanied by hyperacetylation of BCL6 and p53. Cambinol has only weak inhibitory activity against SIRT5 (42% inhibition at 300 μM) and no activity against SIRT3.
Cambinol is well tolerated in mice (100 mg/kg) and inhibits growth of Burkitt lymphoma xenografts. No significant weight loss occurs in cambinol-treated animals relative to controls. Inhibitors of NAD-dependent deacetylases may constitute novel anticancer agents.